Case study: enabling double dose methodology on Reveos through pathogen inactivation

Ms. Eleonore Tennby
Cerus Europe B.V.
Amersfoort, the Netherlands

Global Headquarters

1220 Concord Avenue

Concord, CA US 94520

+1 925.288.6000

European Headquarters

Stationsstraat 79-D

3811 MH Amersfoort, Netherlands

+31 (0) 33 49 60 600

Cookie Notice
Legal
Privacy Policy
Follow us

The information on this site is not country-specific, and may contain information that is outside the approved indications for the country in which you are located. Use of INTERCEPT Plasma or Platelets is contraindicated in patients with a history or allergic response to amotosalen or psoralens. Consult instructions for use for indications, contraindications, warnings, and precautions.

Cerus, INTERCEPT and the Cerus logo are trademarks of Cerus Corporation.

© 2025 Cerus Corporation. Cerus. Cerus, INTERCEPT, and the Cerus logo are registered trademarks of Cerus Corporation. MKT-EN 00860 MKT-EN 00861 MKT-EN 00844 MKT-EN 00857 MKT-EN 00858 MKT-EN 00859 MKT-EN 00856 MKT-EN 00855 MKT-EN 00854 MKT-EN 00853 MKT-EN 00852 MKT-EN 00851 MKT-EN 00850 MKT-EN 00849 MKT-EN 00848 MKT-EN 00847 MKT-EN 00846 MKT-EN 00845